The role of ultrasound in the detection of endometrial pathologies in asymptomatic postmenopausal breast cancer patients with tamoxifen treatment

Obstetrical and Gynecological Survey

Volumn 53, Issue 7, 1998, Pages 429-438

  Cohen, Ilan ^a   Beyth, Yoram ^b   Tepper, Ron ^b  

^a MEIR MEDICAL CENTER   (Israel)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

TAMOXIFEN;

BREAST CANCER; CLINICAL TRIAL; DOPPLER ECHOGRAPHY; ENDOMETRIUM CARCINOMA; ENDOMETRIUM HYPERPLASIA; FOLLOW UP; HUMAN; HYSTEROGRAPHY; POLYP; POSTMENOPAUSE; REVIEW; TRANSVAGINAL ECHOGRAPHY;

AFTERCARE; ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; DECISION TREES; DRUG MONITORING; ENDOMETRIAL HYPERPLASIA; ENDOMETRIAL NEOPLASMS; ENDOSONOGRAPHY; FEMALE; HUMANS; HYSTEROSALPINGOGRAPHY; MIDDLE AGED; POSTMENOPAUSE; TAMOXIFEN; ULTRASONOGRAPHY, DOPPLER, COLOR; ULTRASONOGRAPHY, DOPPLER, PULSED; VAGINA;

EID: 0031820591     PISSN: 00297828     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006254-199807000-00023     Document Type: Review

References (79)

1. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy. Lancet 1992;339:1, 71.
2. Neven P, De Muylder X, Van Belle Y et al. Tamoxifen and the uterus and endometrium. Lancet 1989;2:375.
3. De Muylder X, Neven P, DeSomer M. Endometrial lesions in patients undergoing tamoxifen therapy. Int J Gynecol Oncol 1991;36:127.
4. Cohen I, Rosen DJD, Shapira J et al. Endometrial changes in postmenopausal women treated with tamoxifen for breast cancer. Br J Obstet Gynaecol 1993;100:567.
5. Lahti E, Blanco G, Kauppila A et al. Endometrial changes in postmenopausal breast cancer patients receiving tamoxifen. Obstet Gynecol 1993;81:660.
6. Cohen I, Rosen DJD, Shapira J et al. Endometrial changes with tamoxifen: comparison between tamoxifen-treated and nontreated asymptomatic postmenopausal breast cancer patients. Gynecol Oncol 1994;52:185.
7. Cohen I, Tepper R, Rosen D et al. Continuous tamoxifen treatment in asymptomatic, postmenopausal treated breast cancer patients does not cause aggravation of endometrial pathologies. Gynecol Oncol 1994;55:138.
8. Kedar RP, Bourne TH, Powels TJ et al. Effects of tamoxifen on uterus and ovaries of postmenopausal women in a randomized breast cancer prevention trial. Lancet 1994;343:1318.
9. Ismail SM. Pathology of endometrium treated with tamoxifen. J Clin Pathol 1994;47:827.
10. Borenstein J, Auslender R, Parscal B et al. Diagnostic pitfalls of ultrasonographic uterine screening in women treated with tamoxifen. J Reprod Med 1994;39:674.
11. Cohen I, Altaras MM, Shapira J et al. Time-dependent effect of tamoxifen therapy on endometrial pathologies in asymptomatic postmenopausal breast cancer patients. Int J Gynecol Pathol 1996;15:152.
12. Hann LE, Giess CS, Bach AM et al. Endometrial thickness in tamoxifen-treated patients: Correlation with clinical and pathologic findings. AJR 1997;168:657.
13. Cohen I, Altaras MM, Shapira J et al. Different coexisting endometrial histological features in asymptomatic, postmenopausal breast cancer patients treated with tamoxifen. Obstet Gynecol Invest 1997;43:60.
14. Cohen I, Bernheim J, Shapira J et al. Different coexisting gynecological and endometrial pathologies in postmenopausal breast cancer patients treated with tamoxifen. Obstet Gynecol Invest, In press.
15. Cohen I, Shapira J, Beyth Y et al. Estrogen and progesterone receptors expression in postmenopausal tamoxifen exposed endometrial pathologies. Gynecol Oncol 1997;67:8.
16. Nuovo MA, Nuovo GJ, McCaffrey RM et al. Endometrial polyps in postmenopausal patients receiving tamoxifen. Int J Gynecol Pathol 1989;8:125.
17. Corley D, Rome J, Curtis MT et al. Postmenopausal bleeding from unusual endometrial polyps in women on chronic tamoxifen therapy. Obstet Gynecol 1992;79:111.
18. Cohen I, Beyth Y, Altaras MM et al. Value of sonohysterography in asymptomatic, postmenopausal tamoxifen-treated patients. Gynecol Oncol 1997;64:386.
19. Killackey MA, Hakes TB, Pierce VK. Endometrial adenocarcinoma in breast cancer patients receiving antiestrogens. Cancer Treat Rep 1985;69:237.
20. Hardell L. Tamoxifen as a risk factor for carcinoma of corpus uteri. Lancet 1988;3:563.
21. Malfetano JH. Tamoxifen-associated endometrial carcinoma in postmenopausal breast cancer patients. Gynecol Oncol 1990;39:82.
22. Fornander T, Rutqvist LE, Cedermark B et al. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancers. Lancet 1989;1:117.
23. Wilkins N, Hjalmar ML. Adjuvant tamoxifen in early breast cancer: Occurrence of new primary cancer. Lancet 1989;21: 117.
24. Andersson M, Storm HH, Mouridsen HT. Incidence of new primary cancers after adjuvant tamoxifen and radiotherapy for early breast cancer. J Natl Cancer Inst 1991;83:1013.
25. Sagna RA, Dottino PR, Deligdisch L et al. Tamoxifen and endometrial cancer. Mt Sinai J Med 1992;59:416.
26. Magriples U, Naftolin F, Schwartz PE et al. High-grade endometrial carcinoma in tamoxifen-treated breast cancer patients. J Clin Oncol 1993;11:485.
27. Seoud MA-F, Johnson J, Weed JC. Gynecologic tumors in tamoxifen-treated women with breast cancer. Obstet Gynecol 1993;82:165.
28. Fornander T, Hellstrom A-C, Moberger B. Descriptive clinico-pathologic study of 17 patients with endometrial cancer during or after adjuvant tamoxifen in early breast cancer. J Natl Cancer Inst 1993;85:1850.
29. Fisher B, Costantino JP, Redmond CK et al. Endometrial cancer in tamoxifen-treated breast cancer patients: Findings from the National Surgical Adjuvant Breast and Bowel Project (NSABP) B-14. J Natl Cancer Inst 1994;86:527.
30. van Leeuwen, FE, Benraadt J, Coebergh JW et al. Risk of endometrial cancer after tamoxifen treatment of breast cancer. Lancet 1994;343:448.
31. Barakat RF, Wang G, Curtin J et al. Tamoxifen use in breast cancer patients who subsequently develop corpus cancer is not associated with a higher incidence of adverse histologic features. Gynecol Oncol 1994;55:164.
32. Rutquist LE, Johanson H, Signomakalo T et al. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. J Natl Cancer Inst 1995;87:645.
33. Cook LS, Wiess NS, Schwartz SM et al. Population-based study of tamoxifen therapy and subsequent ovarian, endometrial, and breast cancers. J Natl Cancer Inst 1995;87:1359.
34. Robinson DC, Bloss JD, Schino MA. A retrospective study of tamoxifen and endometrial cancer in breast cancer patients. J Natl Cancer Inst 1995;59:186.
35. Silva EG, Tornos C, Malpia A et al. Uterine neoplasm in patients with tamoxifen. J Cell Biochem Suppl 1995;23:179.
36. Sasco AJ, Chaplous KJ, Amoros E et al. Endometrial cancer following breast cancer: Effect of tamoxifen and castration by radiotherapy. Epidemiology 1996;23:179.
37. Cuena RE, Giachino J, Arendondo MA et al. Endometrial carcinoma associated with breast carcinoma: Low incidence with tamoxifen use. Cancer 1996;77:2058.
38. Fleisher AC, Kalemeris C, Machic JE et al. Sonographic depiction of normal and abnormal endometrium with histopathologic correlation. J Ultrasound Med 1986;5:445.
39. Forrest TS, Elyaderani MK, Muilenburg MI et al. Cyclic endometrial changes: US assessment with histologic correlation. Radiology 1988;167:233.
40. Goldstein SR, Nachtigall M, Snyder JR et al. Endometrial assessment by vaginal ultrasonography before endometrial sampling in patients with postmenopausal bleeding. Am J Obstet Gynecol 1990;163:119.
41. Varner RE, Sparks JM, Cameron CD et al. Transvaginal sonography of the endometrium in postmenopausal women. Obstet Gynecol 1991;78:195.
42. Nasri MN, Shepard JH, Stechell ME et al. The role of vaginal scan in measurement of endometrial thickness in postmenopausal women. Br J Obstet Gynaecol 1991;98:470.
43. Fleischer AC, Mendelson EB, Bohn-Valez M et al. Transvaginal and transabdominal sonography of the endometrium. Semin Ultrasound 1988;9:81.
44. Nasri MN, Coas GJ. Correlation of ultrasound findings and endometrial histopathology in postmenopausal women. Br J Obstet Gynaecol 1989;96:1333.
45. Lin MC, Gosnik BB, Wolf SI et al. Endometrial thickness after menopause: Effect of hormone replacement. Radiology 1991; 180:427.
46. Granberg S, Wikland M, Karlsson B et al. Endometrial thickness as measured by endovaginal ultrasonography for identifying endometrial abnormality. Am J Obstet Gynecol 1991; 164:47.
47. Cohen I, Rosen DJD, Tepper R et al. Ultrasonographic evaluation of the endometrium with correlation to endometrial sampling in postmenopausal patients treated with tamoxifen. J Ultrasound Med 1993;5:275.
48. Uziely B, Lewin E, Brufman G et al. The effect of tamoxifen on the endometrium. Breast Cancer Res Treat 1993;26:101.
49. Sismondi P, Biglia N, Volpi E et al. Tamoxifen and endometrial cancer. NY Acad Science 1994;734:310.
50. Hulka CA, Hall DA. Endometrial abnormalities associated with tamoxifen therapy for breast cancer: Sonographic and pathologic correlation. Am J Radiol 1993;160:809.
51. Anteby E, Yagel S, Zacut D et al. False sonographic appearance of endometrial neoplasia in postmenopausal women treated with tamoxifen (lettr). Lancet 1992;340:433.
52. Perrot N, Goyot B, Antonine M et al. The effect of tamoxifen on the endometrium (lettr). Ultrasound Obstet Gynecol 1994; 4:83.
53. Goldstein SR. Unusual ultrasonographic appearance of the uterus in patients receiving tamoxifen. Am J Obstet Gynecol 1994;170:447.
54. Anteby E, Yagel S, Hochner-Celnikier D. Unusual ultrasonographic appearance of uterus in postmenopausal patients receiving tamoxifen (lettr). Am J Obstet Gynecol 1995;172: 717.
55. Anteby EY, Yagel S, Weissman A et al. Sonographic evaluation of the uterus in postmenopausal women receiving tamoxifen: Characterization of miduterine abnormalities. Eur J Obstet Gynecol Reprod Biol 1996;69:115.
56. Cecchini S, Ciatto S, Bonardi R et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients under adjuvant tamoxifen. Gynecol Oncol 1996;60:409.
57. Cohen I, Altaras MM, Tepper R et al. Screening by ultrasonography for endometrial carcinoma in postmenopausal breast cancer patients with tamoxifen treatment (lettr). Gynecol Oncol 1996;64:412.
58. Pepper JM, Oyesnya OA, Dewart PJ et al. Indices of differential endometrial: Myometrial growth may be used to improve reliability of detecting endometrial neoplasia in women on tamoxifen. Ultrasound Obstet Gynecol 1996;8:408.
59. Ciatto S, Cecchini S, Bonardi R et al. Ultrasonography surveillance of endometrium in breast cancer patients on adjuvant tamoxifen (lettr). Lancet 1994;344:60.
60. Exacoustos C, Zupi E, Cangi B et al. Endometrial evaluation in postmenopausal breast cancer patients receiving tamoxifen: An ultrasound, color flow Doppler, hysteroscopic and histologic study. Ultrasound Obstet Gynecol 1995;6:435.
61. Achiron R, Lipitz S, Sivan E et al. Changes mimicking endometrial neoplasia in postmenopausal tamoxifen-treated women with breast cancer: A transvaginal Doppler study. Ultrasound Obstet Gynecol 1995;6:116.
62. Bourne TH, Campbell S, Whitehead MI et al. Detection of endometrial cancer in postmenopausal women by transvaginal ultrasonography and color flow imaging. Br J Obstet Gynecol 1990;301:369.
63. Bourne TH, Campbell S, Steer CV et al. Detection of endometrial cancer by transvaginal ultrasonography with color flow imaging and blood flow analysis: A preliminary report. Gynecol Oncol 1991;40:253.
64. Tepper R, Cohen I, Altaras MM et al. Doppler flow evaluation of pathologic endometrial conditions in postmenopausal breast cancer patients treated with tamoxifen. J Ultrasound Med 1994;13:635.
65. Uzan S, Perrot N, Uzan M. Tamoxifen: Vaginosonography and color Doppler assessment of the uterus (lettr). Ultrasound Obstet Gynecol 1992;2:306.
66. Achiron R, Lipitz S, Frenkel Y et al. Endometrial blood flow response to estrogen replacement therapy and tamoxifen in asymptomatic, postmenopausal women: A transvaginal Doppler study. Ultrasound Obstet Gynecol 1995;5:411.
67. Beyth Y, Beller U, Yarkoni S. A simple technique for visualization of the uterine cavity and its pathology during ultrasound scanning. Isr J Med Sci 1982;18:817.
68. Parsons AK, Lense JJ. Sonohysterography for endometrial abnormalities: Preliminary results. J Clin Ultrasound 1993;21: 87.
69. Widrich T, Bradley LD, Mitchinson AR et al. Comparison of saline infusion sonography with office hysteroscopy for the evaluation of the endometrium. Am J Obstet Gynecol 1996; 174:1327.
70. Bourne TH, Lawton F, Leather A et al. Use of intracavitary saline instillation and transvaginal ultrasonography to detect tamoxifen-associated polyps. Ultrasound Obstet Gynecol 1994;4:73.
71. Achiron R, Lipitz S, Sivan E et al. Sonohysterography for ultrasonographic evaluation of tamoxifen-associated cystic thickened endometrium. J Ultrasound Med 1995;14:685.
72. Kurman RJ, Kaminski PF, Norris HJ. The behavior of endometrial hyperplasia: A long-term study of "untreated" hyperplasia in 170 patients. Cancer 1985;56:403.
73. Deleted in proof.
74. Armenia CS. Sequential relationship between endometrial polyps and carcinoma of the endometrium. Obstet Gynecol 1967;30:524.
75. Jordan VC, Assikis VJ. Endometrial carcinoma and tamoxifen: Clearing up a controversy. Clin Cancer Res 1995;1:467.
76. Horwitz RI, Feinstein AR. Estrogens and endometrial cancer: Responses to arguments and current status of an epidemiological controversy. Am J Med 1986;81:503.
77. FDA. Zeneca Pharmaceuticals warn of increased uterine-cancer risk with tamoxifen treatment. Am J Hosp Pharm 1994; 51:1380.
78. Osmers R, Volksen M, Schauer A. Vaginosonography for early detection of endometrial carcinoma? Lancet 1990;335:1569.
79. Zacchi V, Zini R, Canino A. Transvaginal sonography as a screening method for the identification of patients at risk of postmenopausal endometrial pathology. Minerva Ginecol 1993;45:339.